SuperGen
Dublin, California, United States
About SuperGen
SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. Products in Development MP-470–DNA Repair Suppressor: MP-470 is a multi-targeted Tyrosine Kinase Inhibitor that is specific for mutant forms of c-kit, PDGFRa, and FLT3. These protein kinase targets are involved in the growth and proliferation of cancer cells. MP-470 is also a suppressor of Rad51, a DNA repair protein which is involved in resistance to various chemotherapy agents and radiation. SuperGen, Inc. was founded in 1991.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $10.6M
- Last round: Series Unknown (Oct 2009)
- Website: supergen.com
- Phone: +1 925-560-0100
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/supergen-2484630 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.